Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orilanolimab - Alexion AstraZeneca Rare Disease

Next Previous
X
Search
Drug Profile

Orilanolimab - Alexion AstraZeneca Rare Disease

Alternative Names: ALXN 1830; SYNT-001; SYNT1001

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntimmune
  • Developer Alexion AstraZeneca Rare Disease; Syntimmune
  • Class Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Fc receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune haemolytic anaemia; Myasthenia gravis; Pemphigus; Unspecified

Most Recent Events

  • 03 Mar 2022 Discontinued - Phase-I for Autoimmune haemolytic anaemia (In volunteers) in New Zealand (SC) (Alexion Pharmaceuticals pipeline, March 2022)
  • 03 Mar 2022 Discontinued - Phase-I for Myasthenia gravis (In volunteers) in New Zealand (SC) (Alexion Pharmaceuticals pipeline, March 2022)
  • 03 Mar 2022 Discontinued - Phase-I for Myasthenia gravis (In volunteers) in USA (SC) (Alexion Pharmaceuticals pipeline, March 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top